[ad_1]
Abdi İbrahim became the second largest shareholder in Swiss OM Pharma. TL 4.2 billion was paid for 28.5 percent of the company’s shares. Abdi İbrahim, Chairman of the Board of Directors, Nezih Barut, announced at the online press conference that they are a strategic partner of OM Pharma, a biotechnology company operating in Switzerland. Barut announced that last night the negotiations that began on January 23 were concluded. Barut said, “We gave the best offer.” Abdi İbrahim acquired Swiss OM Pharma with a group of Swiss joint ventures.
BIOTECHNOLOGICAL DRUGS WILL BE PRODUCED
Noting that they became strategic partners of OM Pharma with the purchase of shares, Barut said: “The perception that Turkish pharmaceutical companies are sold to foreign companies has changed.” Gunpowder, with OM Pharma will produce some chemical drugs in Turkey, said the sağlayacaklat the production of biotech drugs.
SELL DRUGS TO 65 COUNTRIES
The foundations of OM Pharma, a biotechnology pharmaceutical company that develops medicines in the field of the respiratory tract and urinary system, were established in 1937. The biotech medicines produced by Geneva-based OM Pharma are sold in 65 countries and in a geography from European countries to Latin America, from China to Russia.
